...
首页> 外文期刊>Annals of Clinical and Translational Neurology >Metachromatic leukodystrophy and transplantation: remyelination, no cross‐correction
【24h】

Metachromatic leukodystrophy and transplantation: remyelination, no cross‐correction

机译:成像性白科医养和移植:重新髓鞘,没有交叉矫正

获取原文
           

摘要

Objective In metachromatic leukodystrophy, a lysosomal storage disorder due to decreased arylsulfatase A activity, hematopoietic stem cell transplantation may stop brain demyelination and allow remyelination, thereby halting white matter degeneration. This is the first study to define the effects and therapeutic mechanisms of hematopoietic stem cell transplantation on brain tissue of transplanted metachromatic leukodystrophy patients. Methods Autopsy brain tissue was obtained from eight (two transplanted and six nontransplanted) metachromatic leukodystrophy patients, and two age‐matched controls. We examined the presence of donor cells by immunohistochemistry and microscopy. In addition, we assessed myelin content, oligodendrocyte numbers, and macrophage phenotypes. An unpaired t‐test, linear regression or the nonparametric Mann–Whitney U‐test was performed to evaluate differences between the transplanted, nontransplanted, and control group. Results In brain tissue of transplanted patients, we found metabolically competent donor macrophages expressing arylsulfatase A distributed throughout the entire white matter. Compared to nontransplanted patients, these macrophages preferentially expressed markers of alternatively activated, anti‐inflammatory cells that may support oligodendrocyte survival and differentiation. Additionally, transplanted patients showed higher numbers of oligodendrocytes and evidence for remyelination. Contrary to the current hypothesis on therapeutic mechanism of hematopoietic cell transplantation in metachromatic leukodystrophy, we detected no enzymatic cross‐correction to resident astrocytes and oligodendrocytes. Interpretation In conclusion, donor macrophages are able to digest accumulated sulfatides and may play a neuroprotective role for resident oligodendrocytes, thereby enabling remyelination, albeit without evidence of cross‐correction of oligo‐ and astroglia. These results emphasize the importance of immunomodulation in addition to the metabolic correction, which might be exploited for improved outcomes.
机译:目的在异形白细胞上的目的,由于芳基硫酸淀粉酶降低,溶酶体储存障碍,造血干细胞移植可能阻止脑脱髓鞘并允许重新髓鞘,从而停止白质变性。这是第一项研究,用于确定造血干细胞移植对移植的异形白科患者脑组织造血干细胞移植的效果和治疗机制。方法从八次(两个移植和六个非植入的)的异形白科医生患者和两个匹配的对照中获得尸检脑组织。我们通过免疫组织化学和显微镜检查了供体细胞的存在。此外,我们评估了髓鞘含量,少突胶质细胞数和巨噬细胞表型。进行未配对的T检验,线性回归或非参数曼 - 惠特尼U-Test以评估移植,非筛选和对照组之间的差异。导致移植患者的脑组织,我们在整个白土中发现了表达芳基硫酸糖苷酶A的代谢态有能力巨噬细胞。与非翻译患者相比,这些巨噬细胞优先表达了可支持oligodendrocyte存活和分化的可选激活的抗炎细胞的标志物。此外,移植的患者显示出较高数量的少突胶质细胞和核髓序列的证据。与目前对成群质白科医疗造血细胞移植治疗机制的目前的假设相反,我们检测到驻留星形细胞和少突胶质细胞的酶促交叉。解释总结,供体巨噬细胞能够消化积累的硫酸盐,并且可能为常规寡核细胞发挥神经保护作用,从而能够进行重新髓鞘,尽管没有寡核苷酸和星形菌尿素的交叉矫正证据。这些结果外,除了代谢校正之外,免疫调节的重要性,这可能被利用改善的结果。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号